Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

PARP inhibitors olaparib and talazoparib as treatment for metastatic breast cancer

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 18.06.19
Views: 329
Rating:

Dr Matteo Lambertini - San Martino Hospital, Genoa, Italy

Dr Matteo Lambertini talks to ecancer at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting about two PARP inhibitor agents that are approved for treatment in metastatic breast cancer.

He explains that they have been studied in two similar randomised trials showing similarly promising results.

Dr Lambertini explains that going forward it is key to understand whether these agents can be used in the early setting but that trials are underway researching this.

This programme has been supported by an unrestricted educational grant from Pfizer.

Related videos

follow us

Immuno-oncology advances in cancer treatment e-learning


Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation